WHO IDH突变型胶质瘤诊断更新
本文基于WHO中枢神经系统肿瘤分类第5版(WHO CNS5)及相关文献,综述IDH突变型胶质瘤在分类与命名上的变化。分类建立了必要和可取标准,并首次将分子特征不仅用于分类,还可能影响分级。WHO CNS5分类向基于肿瘤生物学并服务临床需求的方向推进。
要点
- WHO CNS5对IDH突变型胶质瘤的分类和命名进行了更新。
- 分类建立了必要和可取标准,考虑了技术发展。
- 分子特征首次不仅用于IDH突变型胶质瘤分类,还可能影响分级。
核心结论
- WHO CNS5分类向基于肿瘤生物学并服务临床需求的方向推进。
- IDH突变型胶质瘤分子领域知识的快速增长预计将进一步细化未来的分类和分级。
研究设计与样本
- 本文为综述,基于WHO中枢神经系统肿瘤分类第5版(WHO CNS5)及相关论文。
主要发现
- 主要变化包括IDH突变型胶质瘤的分类学和命名。
- 建立了分类的必要和可取标准,考虑了技术发展。
- 分子特征首次不仅与IDH突变型胶质瘤的分类相关,还可能影响分级。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The WHO classification of Tumors of the Central Nervous System represents the international standard classification for brain tumors. In 2021 the 5th edition (WHO CNS5) was published, and this review summarizes the changes regarding IDH-mutant gliomas and discusses unsolved issues and future perspectives. METHODS: This review is based on the 5th edition of the WHO Blue Book of CNS tumors (WHO CNS5) and relevant related papers. RESULTS: Major changes include taxonomy and nomenclature of IDH-mutant gliomas. Essential and desirable criteria for classification were established considering technical developments. For the first time molecular features are not only relevant for the classification of IDH-mutant gliomas but may impact grading as well. CONCLUSION: WHO CNS5 classification moves forward towards a classification which is founded on tumor biology and serves clinical needs. The rapidly increasing knowledge on the molecular landscape of IDH-mutant gliomas is expected to further refine classification and grading in the future.
引用
- Reuss DE. Updates on the WHO diagnosis of IDH-mutant glioma. J Neurooncol. 2023. PMID: 36717507. doi:10.1007/s11060-023-04250-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。